Robert G. Urban, PhD

Global Head of Johnson & Johnson Innovation

Robert is Global Head of Johnson & Johnson Innovation and leads Johnson & Johnson’s Boston Innovation Center. Johnson & Johnson Innovation Centers are home to investment teams that work closely with entrepreneurs to advance products and technology up to proof-of- concept across the pharmaceuticals, medical device & diagnostic and consumer sectors. Their investments focus on people and programs that have the potential to not just advance healthcare, but to transform it. Located in Boston, Menlo Park, London and Shanghai, the J&J Innovation Centers seek to simplify and expedite the transformation of discoveries into healthcare products that improve lives across the world.

Prior to J&J, Robert was the founding Executive Director of MIT’s Institute for Integrative Cancer Research. Robert has co-founded multiple biopharmaceutical companies, held a variety of R&D leadership/operational roles and served as an advisor or board member in the industry. Robert received his Bachelor of Arts degree in Microbiology and his Ph.D. in Microbiology and Immunology from the University of Texas system and was an Irvington Fellow in structural immunology at Harvard University.

Kuldeep Neote, Ph.D

Senior Director at J&J Innovation Center-Boston

Dr. Neote is trained as a Molecule Biologist with an extensive background in drug discovery. He has been focused in the area of Immunology, Inflammation and Oncology and has a passion for implementing cutting edge scientific discoveries into practical drug discovery programs. Throughout his career, he has looked at creative scientific and business development collaborative and partnering opportunities that have resulted in tangible clinical translation of new scientific discoveries working in conjunction with academic and biotech companies.

Formerly, Dr. Neote was Research Advisor/Director in Global External R&D at Eli Lilly in Indianapolis, IN. Prior to Eli Lilly, he was a Discovery Scientist in Pfizer Inc. in Groton, CT. Dr. Neote initiated the Chemokine Receptor Drug Discovery platform that lead to several clinical candidates, and also discovered novel chemokines. Earlier in his career, Dr. Neote cloned one of the first chemokine receptors during his post-doctoral studies in Genentech.

Dr. Neote earned her BSc. in Microbial and Cellular Biology at the University of Calgary, Calgary, Canada, and a Ph.D. in Human and Molecule Genetics at the University of Toronto, Toronto, Canada, where he was a major contributor in the understanding of the molecular basis of lysosomal storage diseases, in particular Tay Sachs and Sandhoff’s disease.